Nanoform Finland PLC
Company Profile
Business description
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceuticals pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
Contact
Cultivator II, Viikinkaari 4
Helsinki00790
FINT: +358 293700150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
175
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,236.50 | 29.80 | 0.32% |
| CAC 40 | 8,157.29 | 43.59 | -0.53% |
| DAX 40 | 24,118.89 | 5.32 | -0.02% |
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% |
| FTSE 100 | 9,760.06 | 3.92 | 0.04% |
| HKSE | 26,282.69 | 63.45 | -0.24% |
| NASDAQ | 23,581.14 | 377.33 | -1.57% |
| Nikkei 225 | 51,762.67 | 437.06 | 0.85% |
| NZX 50 Index | 13,500.69 | 41.40 | 0.31% |
| S&P 500 | 6,822.34 | 68.25 | -0.99% |
| S&P/ASX 200 | 8,942.40 | 29.20 | 0.33% |
| SSE Composite Index | 3,986.90 | 29.43 | -0.73% |